JP Morgan Chase’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

JP Morgan Chase’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3	Closed	-$26	–	7788
2024 Q2	$26	Hold	3	–	–	﹤0.01%	7141
2024 Q1	$26	Buy	3 +1	+50%	+$8	﹤0.01%	7141
2023 Q4	$15	Buy	2 +1	+100%	+$7	﹤0.01%	7391
2023 Q3	$6	Buy	+1	New	+$7	﹤0.01%	7349
2022 Q2	–	Sell	-463	Closed	-$10K	–	6991
2022 Q1	$10K	Sell	463 -7,451	-94%	-$258K	﹤0.01%	6216
2021 Q4	$476K	Buy	7,914 +2,376	+43%	+$178K	﹤0.01%	4876
2021 Q3	$520K	Buy	5,538 +2,723	+97%	+$363K	﹤0.01%	4694
2021 Q2	$466K	Sell	2,815 -7,764	-73%	-$1.32M	﹤0.01%	4741
2021 Q1	$2.04M	Buy	+10,579	New	+$2.64M	﹤0.01%	3712

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

JP Morgan Chase's TLIS Position: Q3 2024 in Review

JP Morgan Chase sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 3 shares — an estimated $26 sold.

JP Morgan Chase first reported a position in TLIS in Q1 2021 and held it in 9 quarters. The position peaked at $2.04M in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

JP Morgan Chase reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
JP Morgan Chase sold 3 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $26.
JP Morgan Chase first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 9 quarters.
JP Morgan Chase's Talis Biomedical Corporation Common Stock position peaked at $2.04M in Q1 2021.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.